PM-01: Phase 1b Study of PGG Beta Glucan (Imprime PGG®) in Combination With Anti-MUC1 Antibody (BTH1704) and Gemcitabine (Gemzar®) for the Treatment of Advanced Pancreatic Cancer

Trial Profile

PM-01: Phase 1b Study of PGG Beta Glucan (Imprime PGG®) in Combination With Anti-MUC1 Antibody (BTH1704) and Gemcitabine (Gemzar®) for the Treatment of Advanced Pancreatic Cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 May 2015

At a glance

  • Drugs BTH 1704 (Primary) ; PGG-glucan (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Proof of concept
  • Acronyms PM-01
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Apr 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 08 Sep 2014 Planned primary completion date changed from 1 May 2017 to 1 Aug 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top